SG10201604988YA - Methods and compositions for diagnostic use in cancer patients - Google Patents

Methods and compositions for diagnostic use in cancer patients

Info

Publication number
SG10201604988YA
SG10201604988YA SG10201604988YA SG10201604988YA SG10201604988YA SG 10201604988Y A SG10201604988Y A SG 10201604988YA SG 10201604988Y A SG10201604988Y A SG 10201604988YA SG 10201604988Y A SG10201604988Y A SG 10201604988YA SG 10201604988Y A SG10201604988Y A SG 10201604988YA
Authority
SG
Singapore
Prior art keywords
compositions
methods
cancer patients
diagnostic use
diagnostic
Prior art date
Application number
SG10201604988YA
Inventor
Yibing Yan
Paul J Fielder
Qun Jenny Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10201604988YA publication Critical patent/SG10201604988YA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
SG10201604988YA 2008-12-23 2009-12-22 Methods and compositions for diagnostic use in cancer patients SG10201604988YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14039208P 2008-12-23 2008-12-23

Publications (1)

Publication Number Publication Date
SG10201604988YA true SG10201604988YA (en) 2016-07-28

Family

ID=41664930

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2012092748A SG187385A1 (en) 2008-12-23 2009-12-22 Methods and compositions for diagnostic use in cancer patients
SG10201604988YA SG10201604988YA (en) 2008-12-23 2009-12-22 Methods and compositions for diagnostic use in cancer patients
SG2011046273A SG172355A1 (en) 2008-12-23 2009-12-22 Methods and compositions for diagnostic use in cancer patients

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012092748A SG187385A1 (en) 2008-12-23 2009-12-22 Methods and compositions for diagnostic use in cancer patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011046273A SG172355A1 (en) 2008-12-23 2009-12-22 Methods and compositions for diagnostic use in cancer patients

Country Status (13)

Country Link
US (4) US20100216115A1 (en)
EP (1) EP2382472B1 (en)
JP (1) JP5416221B2 (en)
KR (3) KR101596539B1 (en)
CN (1) CN102265157B (en)
AU (2) AU2009329994B2 (en)
BR (1) BRPI0918211A2 (en)
CA (1) CA2746120A1 (en)
ES (1) ES2541925T3 (en)
IL (2) IL213410A (en)
MX (2) MX2011006875A (en)
SG (3) SG187385A1 (en)
WO (1) WO2010075420A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685382C (en) 2007-05-01 2023-02-21 The Regents Of The University Of California Methods for diagnosing ischemia
CA2804763C (en) 2010-07-14 2023-01-03 The Regents Of The University Of California Biomarkers for diagnosis of transient ischemic attacks
US20120065087A1 (en) 2010-07-15 2012-03-15 Regents Of The University Of California Biomarkers for diagnosis of stroke and its causes
WO2012010548A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
BR112012033423A2 (en) * 2010-07-19 2016-10-25 Hoffmann La Roche methods for improving the effectiveness of treatment of a chemotherapy and in vitro regimen, uses of bevacizumab and specific probes, kit and use of a polypeptide
RU2013104039A (en) * 2010-07-19 2014-08-27 Ф. Хоффманн-Ля Рош Аг METHOD FOR IDENTIFICATION OF A PATIENT WITH AN INCREASED PROBABILITY OF ANSWER TO ANTI-CANCER THERAPY
EP3156800A1 (en) * 2010-07-19 2017-04-19 F. Hoffmann-La Roche AG Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
EP2311865A1 (en) * 2010-11-19 2011-04-20 F. Hoffmann-La Roche AG Placental Growth Factor in Cancer Disease
WO2012121978A2 (en) 2011-03-04 2012-09-13 The Regents Of The University Of California Biomarkers for the diagnosis of lacunar stroke
ES2624981T3 (en) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in the MYD88 gene in lymphoplasmocytic lymphoma
WO2013103781A1 (en) 2012-01-07 2013-07-11 The Regents Of The University Of California Biomarkers for diagnosing ischemia
SG11201403927XA (en) 2012-01-13 2014-08-28 Genentech Inc Biological markers for identifying patients for treatment with vegf antagonists
CN103207274B (en) * 2013-04-28 2015-02-25 成都中医药大学 Screening kit for seventh chromosome abnormality diseases of fetus
CN103235142B (en) * 2013-04-28 2015-04-15 成都中医药大学 First pregnancy screening kit for pregnant woman
CA2922398C (en) * 2013-09-12 2023-08-29 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
EP3077001B1 (en) 2013-12-06 2020-04-15 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
MX2017003015A (en) * 2014-09-17 2017-05-23 Merck Patent Gmbh A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof.
JP2019518006A (en) 2016-04-29 2019-06-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド HCK as a Therapeutic Target in MYD 88 Mutant Disease
CN107037210A (en) * 2017-04-05 2017-08-11 北京蛋白质组研究中心 Application of the THBS2 Protein Detections thing in diagnosis of hepatoma kit is prepared
EP4139475A2 (en) * 2020-04-22 2023-03-01 Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center Exosome analysis and brain tumors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK1167384T3 (en) 1992-10-28 2007-04-10 Genentech Inc Vascular endothelial cell growth factor antagonists
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
TR199902818T2 (en) 1997-04-07 2000-05-22 Genentech, Inc. Methods for creating antibodies for human use and antibodies for human use.
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE69829891T2 (en) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF antibody
UA60365C2 (en) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU2001249727A1 (en) 2000-03-31 2001-10-15 Genentech, Inc. Compositions and methods for detecting and quantifying gene expression
NZ543614A (en) 2003-05-22 2009-09-25 Abbott Lab Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
RS20150135A1 (en) 2003-05-30 2015-08-31 Genentech Inc. Treatment with anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7354580B2 (en) * 2004-06-10 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
JP5164829B2 (en) * 2005-03-24 2013-03-21 トロンボジェニクス・ナムローゼ・フエンノートシャップ Novel anti-PLGF antibody
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
CN101534865A (en) * 2005-10-19 2009-09-16 Ibc药品公司 Methods and compositions for generating bioactive assemblies of increased complexity and uses
AU2007233237A1 (en) * 2006-03-29 2007-10-11 Genentech, Inc. Diagnostics and treatments for tumors
JP4699311B2 (en) * 2006-08-22 2011-06-08 太陽社電気株式会社 Chip resistor

Also Published As

Publication number Publication date
IL213410A0 (en) 2011-07-31
CA2746120A1 (en) 2010-07-01
US20130224193A1 (en) 2013-08-29
US20130022596A1 (en) 2013-01-24
US20100216115A1 (en) 2010-08-26
JP5416221B2 (en) 2014-02-12
AU2014203615A1 (en) 2014-07-17
ES2541925T3 (en) 2015-07-28
AU2009329994A1 (en) 2011-07-07
KR101596539B1 (en) 2016-02-22
US20130224194A1 (en) 2013-08-29
IL213410A (en) 2015-02-26
KR20110106899A (en) 2011-09-29
WO2010075420A1 (en) 2010-07-01
SG187385A1 (en) 2013-02-28
MX2011006875A (en) 2011-07-20
SG172355A1 (en) 2011-07-28
KR20160021308A (en) 2016-02-24
KR20140020368A (en) 2014-02-18
CN102265157B (en) 2014-11-26
EP2382472B1 (en) 2015-05-06
BRPI0918211A2 (en) 2015-12-08
CN102265157A (en) 2011-11-30
IL236786A (en) 2017-05-29
MX2018011832A (en) 2020-09-14
EP2382472A1 (en) 2011-11-02
JP2012513592A (en) 2012-06-14
AU2009329994B2 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
IL213410A0 (en) Methods and compositions for diagnostic use in cancer patients
IL205246A0 (en) Methods and compositions for diagnostic use in cancer patients
IL208458A0 (en) Compositions and methods for skin care
HK1148906A1 (en) Compositions and methods for cancer treatment
IL217540A (en) Oral composition for use in oral disinfection or in treating an oral disease
EP2282672A4 (en) Systems and methods for imaging changes in tissue
EP2180873A4 (en) Therapeutic dental composition and related methods
EP2064550A4 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
HK1170542A1 (en) Methods and compositions for diagnostics use in cancer patients
GB0708761D0 (en) Improvements in and relating to medical instruments
EP2299904A4 (en) Medical diagnostic devices and methods
IL210755A0 (en) Devices and methods for forming tracts in tissue
EP2480687A4 (en) Methods and compositions for the diagnosis and treatment of thyroid cancer
GB0922085D0 (en) Cancer diagnosis and treatment
EP2340851A4 (en) Diagnosis method and therapeutic method for cancer
EP2298365A4 (en) Medical composition and medical kit
GB0918392D0 (en) Diagnostic and therapeutic methods
EP2342559A4 (en) Methods and compositions for preventing artifacts in tissue samples
EP2198041A4 (en) Method and composition for cancer diagnosis and treatment
EP2350001A4 (en) Novel benzylidene-indolinone and their medical and diagnostic uses
GB0919889D0 (en) Drug composition and its use in therapy
HUE031337T2 (en) Opioids for use in the treatment of resistant cancer patients
GB0919893D0 (en) Drug composition and its use in therapy
GB0901837D0 (en) Cancer diagnosis and treatment
GB0910375D0 (en) Drug composition and its use in therapy